SPOKANE, Washington (September 26, 2017) —Pathology Associates Medical Laboratories, LLC (PAML) will host a webinar featuring Oncimmune USA’s Dr. James Jett, Chief Medical Officer and Dr. Laura Peek, Principal Scientist. They will be exploring “Advancements in the Early Detection of Lung Cancer” on October 12, 2016.

EarlyCDT-Lung is a blood test used to aid in the risk assessment and early detection of lung cancer in high risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. With the potential to detect cancer up to four years earlier than other methods, the test is based on the presence of autoantibodies in the blood against specific tumor associated antigens.

According to Greg Stanley, President of Commercial Operations with Oncimmune USA, EarlyCDT-Lung “complements CT lung cancer screenings by providing an alternative to high risk patients who do not meet the eligibility requirements or are unwilling or unable to have an annual CT scan.”  

PACE Credits are available to those who attend the EarlyCDT-Lung webinar. If you are interested in attending or would like to see other webinars hosted by PAML, please visit https://www.paml.com/providers-hospitals/client-education/webinars.